Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeoVax Labs Inc. GOVX

Geovax Labs Inc is us-based clinical-stage biotechnology company. It is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a novel patented Modified Vaccinia Ankara-Virus Like Particle (GV-MVA-VLP) vector vaccine platform. The development programs of the company focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The product pipeline includes HIV Preventive Vaccine, Hemorrhagic Fever Vaccines, Zika Vaccine, Malaria vaccine, and Cancer Immunotherapy.


Recent & Breaking News (NDAQ:GOVX)

GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire 9 days ago

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

GlobeNewswire July 28, 2022

GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

GlobeNewswire July 26, 2022

GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development

GlobeNewswire June 13, 2022

GeoVax to Present at BIO International Convention 2022

GlobeNewswire June 7, 2022

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

GlobeNewswire May 25, 2022

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

GlobeNewswire May 24, 2022

GeoVax Announces Upcoming Presentations at Scientific Conferences

GlobeNewswire May 4, 2022

GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

GlobeNewswire April 27, 2022

GeoVax Announces Issuance of Malaria Vaccine Patent

GlobeNewswire April 26, 2022

GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

GlobeNewswire April 19, 2022

CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option

GlobeNewswire April 18, 2022

Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option

GlobeNewswire April 18, 2022

GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress

GlobeNewswire April 12, 2022

GeoVax Announces Issuance of Cancer Vaccine Patent

GlobeNewswire March 22, 2022

GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022

GlobeNewswire March 21, 2022

GeoVax to Participate in Maxim Group's 2022 Virtual Growth Conference

GlobeNewswire March 16, 2022

GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

GlobeNewswire March 14, 2022

Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2

GlobeNewswire March 10, 2022

GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

GlobeNewswire March 9, 2022